Talking Medicines targets messaging risk in pharma brand strategy

Tern plc

Pharma teams typically begin with a clear brand narrative built on scientific evidence. But as this narrative moves through marketing, compliance and external agencies, the original message can become diluted. When that happens, healthcare professionals may misinterpret or disengage from the brand. The result is weaker positioning, lower impact and reduced return on marketing investment.

Talking Medicines addresses this problem by offering real-time analytics that measure how healthcare professionals actually receive and interpret brand messages. Instead of waiting for post-campaign reports, teams can see early signals of what is working and adjust strategy before value is lost. This is especially relevant during launch phases, where the ability to course-correct quickly can have a material impact on performance.

Its DrugVoice platform captures unstructured HCP dialogue and turns it into structured insight. This data helps brand teams understand whether their messages are understood, aligned with clinical priorities and prompting the right actions. For leadership, it offers a way to verify that brand strategy is being delivered as intended.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search